Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject

a Randomised, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03759743

Enrollment

Registered

2018-11-30

Start date

2018-09-04

Completion date

2020-01-07

Last updated

2020-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight

Brief summary

The purpose of this study is to evaluate the safety and efficacy of LMT1-48(Probiotics) compared to a placebo in reducing the body fat in overweight subjects

Interventions

DIETARY_SUPPLEMENTLMT1-48

capsules containing Probiotics

DIETARY_SUPPLEMENTPlacebo

capsules that did not contain any probiotics

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Age between 19 and 70 years * Overweight (25 kg/m2 ≤ body mass index (BMI) \< 30 kg/m2)

Exclusion criteria

* Pregnancy or breast-feeding * Unstable body weight (body weight change \> 10% within 3 months before screening)

Design outcomes

Primary

Measure	Time frame	Description
change from baseline fat percentage at 12 week	at baseline and 12-week follow-up	the body composition of the subjects was measured via dual-energy X-ray absorptiometry (DEXA) to determine

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026